Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Recent & Breaking News (NDAQ:TVTX)

Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

GlobeNewswire June 19, 2020

Retrophin Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 8, 2020

Retrophin Announces Proposed Public Offering of Common Stock

GlobeNewswire June 8, 2020

Retrophin to Present at the Jefferies 2020 Virtual Healthcare Conference

GlobeNewswire May 27, 2020

Retrophin Reports First Quarter 2020 Financial Results

GlobeNewswire May 11, 2020

Retrophin to Report First Quarter 2020 Financial Results

GlobeNewswire April 27, 2020

Retrophin Appoints Suzanne L. Bruhn, Ph.D. to Board of Directors

GlobeNewswire April 9, 2020

Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

GlobeNewswire March 9, 2020

Retrophin Recognizes Rare Disease Day 2020 and the Importance of Working Together Toward More Equitable Access to Care

GlobeNewswire February 28, 2020

Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 24, 2020

Retrophin to Present at Upcoming Investor Conferences

GlobeNewswire February 19, 2020

Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 13, 2020

Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 10, 2020

Retrophin Provides Corporate Update and 2020 Outlook

GlobeNewswire January 13, 2020

Retrophin to Present at the Jefferies 2019 London Healthcare Conference

GlobeNewswire November 14, 2019

Retrophin Reports Third Quarter 2019 Financial Results

GlobeNewswire October 30, 2019

Retrophin to Report Third Quarter 2019 Financial Results

GlobeNewswire October 16, 2019

Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019

GlobeNewswire October 11, 2019

Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer

GlobeNewswire October 1, 2019

Retrophin to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 26, 2019